Canaccord Genuity Starts Entellus Medical (ENTL) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St set for higher open but weekly losses loom
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Piper Jaffray Starts Entellus Medical (ENTL) at Overweight
February 23, 2015 6:51 AM ESTPiper Jaffray initiates coverage on Entellus Medical (NASDAQ: ENTL) with a Overweight rating and a price target of $25.00.
Analyst Thomas Gunderson comments, "We are initiating ENTL with an Overweight rating and $25 price target. Entellus, a manufacturer and marketer of a balloon dilation product line for... More
BofA/Merrill Lynch Starts Entellus Medical (ENTL) at Buy
February 23, 2015 6:24 AM ESTBofA/Merrill Lynch initiates coverage on Entellus Medical (NASDAQ: ENTL) with a Buy rating and a price target of $26.00.
Analyst Bob Hopkins is bullish on the company's minimally invasive balloon-based alternative to open surgery for treating chronic sinusitis. The device allows doctors to... More
